Laura de la Bastida Casero

Mrs. Laura de la Bastida Casero

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LCLaura de la Bastida Casero
Laura de la Bastida Casero
BGBertha Garcia-Leon
Bertha Garcia-Leon
Olga Tura-CeideOlga Tura-Ceide
Olga Tura-Ceide
Eduardo OliverEduardo Oliver
Eduardo Oliver
The endothelium is a cell monolayer that lines vessels and separates tissues from blood flow. Endothelial cells (ECs) have a multitude of functions, including regulating blood flow and systemic perfusion through changes in vessel diameter. When an injury occurs, the endothelium is affected by altering its functions and structure, which leads to endothelial dysfunction, a characteristic of many vascular diseases. Understanding the role that the endothelium plays in pulmonary vascular and cardiopulmonary diseases, and exploring new therapeutic strategies is of utmost importance to advance clinically. Currently, there are several treatments able to improve patients’ quality of life, however, none are effective nor curative. This review examines the critical role of the endothelium in the pulmonary vasculature, investigating the alterations that occur in ECs and their consequences for blood vessels and potential molecular targets to regulate its alterations. Additionally, we delve into promising non-pharmacological therapeutic strategies, such as exercise and diet. The significance of the endothelium in cardiopulmonary disorders is increasingly being recognized, making ECs a relevant target for novel therapies aimed at preserving their functional and structural integrity.

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSusana F. Rocha
Susana F. Rocha
LCLaura de la Bastida Casero
Laura de la Bastida Casero
MSMonika Spaczyńska-Kwiatkowska
Monika Spaczyńska-Kwiatkowska
Álvaro MacíasÁlvaro Macías
Álvaro Macías
YSYolanda Sierra-Palomares
Yolanda Sierra-Palomares
Eduardo OliverEduardo Oliver
Eduardo Oliver
Background: Pulmonary hypertension (PH) is a progressive vascular disease characterized by endothelial dysfunction, vascular remodeling and increased pulmonary vascular resistance. The β3-adrenergic receptor (β3-AR) has been implicated in cardiovascular regulation and cardioprotective mechanisms; however, its role in pulmonary vascular disease remains poorly understood. We investigated whether activation of β3-AR protects pulmonary endothelial function and prevents the development of pre-capillary PH. Methods: β3-AR expression was evaluated in pulmonary endothelium from patients with Chronic Obstructive Pulmonary Disease (COPD) and in murine models of hypoxia-induced PH. Genetic mouse models including β3-AR knockout (KO) and conditional β3-AR overexpression in endothelial cells (EC) or in smooth muscle cells (SMC), were used to determine cell-specific roles. Pharmacological activation of β3-AR was achieved using the selective β3-agonist mirabegron in hypoxia-induced PH mice and monocrotaline-induced PH rats. Pulmonary vascular reactivity and vasodilatory responses to β3-AR stimulation were evaluated by wire myography in isolated pulmonary arteries. Mechanistic studies were performed in human pulmonary artery endothelial cells (HPAEC) under hypoxic conditions, in human pulmonary arterial smooth muscle cells (HPASMC) and in endothelial nitric oxide synthase (NOS3) KO mice. Results: β3-AR was upregulated in pulmonary endothelium of COPD patients and mice exposed to chronic hypoxia. Genetic deletion of β3-AR aggravated PH, whereas endothelial-specific overexpression attenuated the disease phenotype, reducing right ventricular systolic pressure (RVSP), vascular remodeling and right ventricular (RV) hypertrophy. Activation of β3-AR with mirabegron improved pulmonary hemodynamics, reduced vascular remodeling and preserved RV function. β3-AR activation promoted endothelial nitric oxide synthase (eNOS)-dependent NO production, indirectly inhibiting SMC proliferation. Additionally, β3-AR activation improved mitochondrial fitness in endothelial cells by increasing uncoupling protein 2 (UCP2) expression, reducing reactive oxygen species (ROS) generation and preventing mitochondrial fragmentation. Conclusions: These findings identify endothelial β3-AR as a previously unrecognized regulator of pulmonary vascular homeostasis and provide a strong translational rationale for targeting the β3-adrenergic pathway in PH. Given that mirabegron is already approved for clinical use, our results support its repurposing as a therapeutic strategy for pre-capillary forms of PH.

30 October 2026 in Pulmonary Circulation
Verified
Journal Article
Open access
RSRachel L. Sutcliffe
Rachel L. Sutcliffe
ICIona Cuthbertson
Iona Cuthbertson
SMStephen Moore
Stephen Moore
MSMark Southwood
Mark Southwood
LCLaura de la Bastida Casero
Laura de la Bastida Casero
ESElaine Soon
Elaine Soon
Pulmonary artery ECs from PAH patients display reduced oxidative phosphorylation and increased anabolic and pro‐proliferative effects (“Warburg phenomenon”). TEPP‐46 (allosteric stabilizer of tetrameric PKM2) has beneficial effects in wild‐type and BMPR2‐mutation bearing BOECs, ameliorates the increased right ventricular systolic pressures, and improves survival in Sugen‐hypoxia‐exposed rats. Antagonizing the Warburg effect may offer novel therapeutic options for PAH.